Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

International Journal of Cancer

Volumn 83, Issue 3, 1999, Pages 393-400

  Céfaï, Daniel ^a   Morrison, Briggs W ^b   Sckell, Axel ^a   Favre, Luc ^a   Balli, Marietta ^a   Leunig, Michael ^a   Gimmi, Claude D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CLONAL ANERGY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; GENE TARGETING; IMMUNE RESPONSE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; T LYMPHOCYTE;

3T3 CELLS; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD3; FEMALE; GRAFT REJECTION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RECEPTOR, ERBB-2; T-LYMPHOCYTES; VACCINATION;

EID: 0345493645     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991029)83:3<393::AID-IJC16>3.0.CO;2-M     Document Type: Article

References (23)

1. ARAP, W., PASQUALINI, R. and RUOSLAHTI, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380 (1998).
2. CLARK, G.M., Prognostic and predictive factors, 3rd ed., pp. 461-485, Lippincott-Raven, Philadelphia (1996).
3. DI FIORE, P.P., PIERCE, J.H., KRAUS, M.H., SEGATTO, O., KING, C.R. and AAARONSON, S.A., erbB-2 is a potent oncogene when overexpressed in NIH3T3 cells. Science, 237, 178-182 (1987).
4. DISIS, M.L., CALENOFF, E., MCLAUGHLIN, G., MURPHY, A.E., CHEN, W., GRONER, B., JESCHKE, M., LYDON, N., MCGLYNN, E., LIVINGSTON, R.B., MOE, R. and CHEEVER, M.A., Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54, 16-20 (1994).
5. GUINAN, E., GRIBBEN, J., BOUSSIOTIS, V.A., FREEMAN, G.J. and NADLER, L.M., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84, 3261-3282 (1994).
6. HUANG, A.Y.C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D. and LEVITSKY, H., Role of bone-marrow-derived cells in presenting MHC-class-I-restricted tumor antigens. Science, 264, 961-964 (1994).
7. LOLLINI, P.L., NICOLETTI, G., LANDUZZI, L., DE GIOVANNI, C., ROSSI, I., DI CARLO, E., MUSIANI, P., MULLER, W.J. and NANNI, P., Down-regulation of major-histocompatibility-complex-class-I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer, 77, 937-941 (1998).
8. MORRISON, B.W. and LEDER, P., neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc-and int-2-initiated tumors. Oncogene, 9, 3417-3426 (1994).
9. MULLER, W.J., SINN, E., PATTENGALE, P.K., WALLACE, R. and LEDER, P., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105-115 (1988).
10. OHASHI, P., OEHEN, S., BUERKI, K., PIRCHER, H., OHASHI, C., ODERMATT, B., MALISSEN, B., ZINKERNAGEL, R. and HENGARTNER, H., Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell, 65, 305-317 (1991).
11. OLDSTONE, M.B.A., NERENBERG, M., SOUTHERN, P., PRICE, J. and LEWICKI, H., Virus infection triggers insulin-dependent diabetse mellitus in a transgenic model: role of anti-self(virus) immune response. Cell, 65, 319-331 (1991).
12. PAWELEC, G., ZEUTHEN, J. and KIESSLING, R., Escape from host anti-tumor immunity. Crit. Rev. Oncol., 8, 111-114 (1997).
13. PINKAS, R., SOUSSAN, L., WATERMAN, H., LEVKOWITZ, G., ALROY, I., KLAPPER, L., LAVI, S., SEGER, R., RATZKIN, B., SELA, M. and YARDEN, Y., Diversification of the Neu differentiation factor and epidermal-growth-factor signaling by combinatorial receptor interactions. EMBO J., 15, 2452-2467 (1996).
14. PRESS, M.F., CORDON-CARDO, C. and SLAMON, D.J., Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissue. Oncogene, 5, 953-962 (1990).
15. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. and MCGUIRE, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-181 (1987).
16. SPEISER, D.E., MIRANDA, R., ZAKARIAN, A., BACHMANN, M.F., MCKALL-FAIENZA, K., ODERMATT, B., HANAHAN, D., ZINKERNAGEL, R.M. and OHASHI, P.S., Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. exp. Med., 186, 645-653 (1997).
17. SPRINGER, T.A., Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Ann. Rev. Physiol., 57, 827-872 (1995).
18. STAVELEY-O'CARROLL, K., SOTOMAYOR, E., MONTGOMERY, J., BORRELLO, I., HWANG, L., FEIN, S., PARDOLL, D. and LEVITSKY, H., Induction of antigen-specific T-cell anergy: an early event in the course of tumor progression. Proc. nat. Acad. Sci. (Wash.), 95, 1178-1183 (1998).
19. TOES, R.E., BLOM, R.J., VAN DER VOORT, E., OFFRINGA, R., MELIEF, C.J. and KAST, W.M., Protective anti-tumor immunity induced by immunization with the completely allogeneic tumor cells. Cancer Res., 56, 3782-3787 (1996).
20. TZAHAR, E., WATERMAN, H., CHEN, X., LEVKOWITZ, G., KARUNAGARAN, D., LAVI, S., RATZKIN, B.J. and YARDEN, Y., A hierarchical network of inter-receptor interactions determines signal transduction by NDF/ neuregulin and EGF. Mol cell. Biol., 16, 5276-5287 (1996).
21. VAN DER BRUGGEN, P., TRAVERSARI, C., CHOMEZ, P., LURQUIN, C., DE PLAEN, E., VAN DEN EYNDE, B., KNUTH, A. and BOON, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647 (1991).
22. WALKER, P.R., SAAS, P. and DIETRICH, P.Y., Tumor expression of Fas ligand (CD95L) and its consequences. Curr. Opin. Immunol., 10, 564-572 (1998).
23. YE, X., MCCARRICK, J., JEWETT, L. and KNOWLES, B.B., Timely immunization subverts the development of peripheral non-responsiveness and suppresses tumor development in simian-virus-40-tumor-antigen-transgenic mice. Proc. nat. Acad. Sci. (Wash.), 91, 3916-3920 (1994).